Search

Your search keyword '"Yalniz, Fevzi"' showing total 104 results
Start Over Author "Yalniz, Fevzi" Publication Type Academic Journals
104 results on '"Yalniz, Fevzi"'

1. Matching-Adjusted Indirect Treatment Comparison to Assess the Comparative Efficacy of Ciltacabtagene Autoleucel in CARTITUDE-1 Versus Belantamab Mafodotin in DREAMM-2, Selinexor-Dexamethasone in STORM Part 2, and Melphalan Flufenamide-Dexamethasone in HORIZON for the Treatment of Patients With Triple-Class Exposed Relapsed or Refractory Multiple Myeloma

Author

Weisel, Katja, Krishnan, Amrita, Schecter, Jordan M., Vogel, Martin, Jackson, Carolyn C., Deraedt, William, Yeh, Tzu-min, Banerjee, Arnob, Yalniz, Fevzi, Nesheiwat, Tonia, Van Sanden, Suzy, Diels, Joris, Valluri, Satish, Usmani, Saad Z., Berdeja, Jesus G., Jagannath, Sundar, and Martin, Tom

Published
2022
Full Text
View/download PDF

2. Unveiling the Genetic and Clinical Differences of Acute Myeloid Leukemia (AML) in Obese Patients.

Author

Yalniz, Fevzi F., Johnson, Anna, Alnimer, Yanal, Chahine, Zena, Morris, Trevor, Yadav, Rina, Taj, Hiffsa, Iragavarapu, Chaitanya, Munker, Reinhold, Monohan, Gregory, Wai, Sainan, Zhang, Shulin, Nozad, Sahar, and Qasrawi, Ayman

Subjects
*ACUTE myeloid leukemia, *GENETIC profile, *OVERALL survival, *GENETIC mutation, *OBESITY
Abstract

ABSTRACT Background Methods Results Conclusions The molecular architecture of acute myeloid leukemia (AML) is heterogeneous. Obesity has been identified as a risk factor for the development of AML. There remains a scarcity of data elucidating the specific genetic profile of AML in obese patients.We conducted a review of adult patients treated at our institution for newly diagnosed AML from January 1, 2017, to January 1, 2023. Obesity is defined as BMI > 30 kg/m2. Demographic, clinical, laboratory, and pathologic data were collected retrospectively. The primary outcome of interest was the molecular features of obese compared to non‐obese AML patients. The secondary outcome was overall survival (OS). Inverse probability of treatment weights (IPTW) used to balance both groups on several confounding variables.A total of 185 patients were included in the analysis. 90 (49%) were obese. Compared with non‐obese patients, obese patients were younger and more likely to be females (55 vs. 63, p = 0.04, 55% vs. 38%, p value, p = 0.02, respectively). After matching on age, gender, and ethnicity, obese patients exhibit lower rates of total number of gene mutations (median 2.7 vs. 3.2, p = 0.05), significantly lower rates of mutations in transcriptional factor genes (15.7% vs. 33.2%, p = 0.01), and near‐significant in spliceosome genes (12% vs. 22.3%, p = 0.08), and higher rates of NPM1 mutation (23.3% vs. 12.6%, p = 0.08). Median OS was not significantly different in the matched cohort.The molecular features of obese AML patients significantly differ from non‐obese counterparts. These findings suggest distinct underlying mechanisms in leukemogenesis in obese patients. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

3. Prognostic Role of Gene Mutations in Chronic Myelomonocytic Leukemia Patients Treated With Hypomethylating Agents.

Author

Duchmann, Matthieu, Yalniz, Fevzi, Sanna, Alessandro, Sallman, David, Coombs, Catherine, Renneville, Aline, Kosmider, Olivier, Braun, Thorsten, Platzbecker, Uwe, Willems, Lise, Adès, Lionel, Fontenay, Michaela, Rampal, Raajit, Padron, Eric, Droin, Nathalie, Preudhomme, Claude, Santini, Valeria, Patnaik, Mrinal, Fenaux, Pierre, Solary, Eric, and Itzykson, Raphael

Subjects
Chronic myelomonocytic leukemia, Hypomethylating agents, Prognosis, Somatic mutations, Aged, Azacitidine, Core Binding Factor Alpha 2 Subunit, DNA-Binding Proteins, Decitabine, Dioxygenases, Female, High-Throughput Nucleotide Sequencing, Humans, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Male, Mutation, Proto-Oncogene Proteins, Repressor Proteins
Abstract

Somatic mutations contribute to the heterogeneous prognosis of chronic myelomonocytic leukemia (CMML). Hypomethylating agents (HMAs) are active in CMML, but analyses of small series failed to identify mutations predicting response or survival. We analyzed a retrospective multi-center cohort of 174 CMML patients treated with a median of 7 cycles of azacitidine (n = 68) or decitabine (n = 106). Sequencing data before treatment initiation were available for all patients, from Sanger (n = 68) or next generation (n = 106) sequencing. Overall response rate (ORR) was 52%, including complete response (CR) in 28 patients (17%). In multivariate analysis, ASXL1 mutations predicted a lower ORR (Odds Ratio [OR] = 0.85, p = 0.037), whereas TET2mut/ASXL1wt genotype predicted a higher CR rate (OR = 1.18, p = 0.011) independently of clinical parameters. With a median follow-up of 36.7 months, overall survival (OS) was 23.0 months. In multivariate analysis, RUNX1mut (Hazard Ratio [HR] = 2.00, p = .011), CBLmut (HR = 1.90, p = 0.03) genotypes and higher WBC (log10(WBC) HR = 2.30, p = .005) independently predicted worse OS while the TET2mut/ASXL1wt predicted better OS (HR = 0.60, p = 0.05). CMML-specific scores CPSS and GFM had limited predictive power. Our results stress the need for robust biomarkers of HMA activity in CMML and for novel treatment strategies in patients with myeloproliferative features and RUNX1 mutations.

Published
2018

4. Characteristics and Outcomes of Patients With Multiple Myeloma Who Developed Therapy-Related Acute Myeloid Leukemia and Myelodysplastic Syndrome After Autologous Cell Transplantation

Author

Yalniz, Fevzi F., Greenbaum, Uri, Pasvolsky, Oren, Milton, Denái R., Kanagal-Shamanna, Rashmi, Ramdial, Jeremy, Srour, Samer, Mehta, Rohtesh, Alousi, Amin, Popat, Uday R., Nieto, Yago, Kebriaei, Partow, Al-Atrash, Gheath, Oran, Betul, Hosing, Chitra, Ahmed, Sairah, Champlin, Richard E., Shpall, Elizabeth J., Qazilbash, Muzaffar H., and Bashir, Qaiser

Published
2024
Full Text
View/download PDF

5. Outcomes of Second Allogeneic Hematopoietic Cell Transplantation for Patients With Acute Myeloid Leukemia

Author

Yalniz, Fevzi F., Saliba, Rima M., Greenbaum, Uri, Ramdial, Jeremy, Popat, Uday, Oran, Betul, Alousi, Amin, Olson, Amanda, Alatrash, Gheath, Marin, David, Rezvani, Katayoun, Hosing, Chitra, Im, Jin, Mehta, Rohtesh, Qazilbash, Muzaffar, Joseph, Jacinth Joy, Rondon, Gabriela, Kanagal-Shamanna, Rashmi, Shpall, Elizabeth, Champlin, Richard, and Kebriaei, Partow

Published
2021
Full Text
View/download PDF

6. CRP and ferritin in addition to the EASIX score predict CAR-T–related toxicity

Author

Greenbaum, Uri, Strati, Paolo, Saliba, Rima M., Torres, Janet, Rondon, Gabriela, Nieto, Yago, Hosing, Chitra, Srour, Samer A., Westin, Jason, Fayad, Luis E., Lee, Hun J., Iyer, Swaminathan P., Nair, Ranjit, Nastoupil, Loretta J., Parmar, Simrit, Rodriguez, Maria A., Samaniego, Felipe, Steiner, Raphael E., Wang, Michael, Pinnix, Chelsea C., Flowers, Christopher R., Tummala, Sudhakar, Ramdial, Jeremy L., Yalniz, Fevzi F., Hawkins, Misha, Rezvani, Katayoun, Champlin, Richard E., Shpall, Elizabeth J., Neelapu, Sattva S., Kebriaei, Partow, and Ahmed, Sairah

Published
2021
Full Text
View/download PDF

11. Outcomes of Chronic Myeloid Leukemia Patients With Early Molecular Response at 3 and 6 Months: A Comparative Analysis of Generic Imatinib and Glivec

Author

Eskazan, Ahmet Emre, Sadri, Sevil, Keskin, Dilek, Ayer, Mesut, Kantarcioglu, Bulent, Demirel, Naciye, Aydin, Demet, Aydinli, Fuat, Yokus, Osman, Ozunal, Isil Erdogan, Berk, Selin, Yalniz, Fevzi Firat, Elverdi, Tugrul, Salihoglu, Ayse, Ar, Muhlis Cem, Ongoren, Seniz, Baslar, Zafer, Aydin, Yildiz, Tuzuner, Nukhet, Ozbek, Ugur, and Soysal, Teoman

Published
2017
Full Text
View/download PDF

13. Impact of numerical variation, allele burden, mutation length and co-occurring mutations on the efficacy of tyrosine kinase inhibitors in newly diagnosed FLT3- mutant acute myeloid leukemia

Author

Abou Dalle, Iman, Ghorab, Ahmad, Patel, Keyur, Wang, Xuemei, Hwang, Hyunsoo, Cortes, Jorge, Issa, Ghayas C., Yalniz, Fevzi, Sasaki, Koji, Chihara, Dai, Price, Allyson, Kadia, Tapan, Pemmaraju, Naveen, Daver, Naval, DiNardo, Courtney, Ravandi, Farhad, Kantarjian, Hagop M., and Borthakur, Gautam

Published
2020
Full Text
View/download PDF

18. Therapeutical potential of autologous peripheral blood mononuclear cell transplantation in patients with type 2 diabetic critical limb ischemia

Author

Ozturk, Ahmet, Kucukardali, Yasar, Tangi, Fatih, Erikci, Alev, Uzun, Gunalp, Bashekim, Cınar, Sen, Huseyin, Terekeci, Hakan, Narin, Yavuz, Ozyurt, Mustafa, Ozkan, Sezai, Sayan, Ozkan, Rodop, Osman, Nalbant, Selim, Sıldıroglu, Onur, Yalnız, Fevzi Firat, Senkal, İbrahim Volkan, Sabuncu, Hilmi, and Oktenli, Cagatay

Published
2012
Full Text
View/download PDF

28. 220 - Cartitude-5: A Randomized, Phase 3 Study of Bortezomib, Lenalidomide and Dexamethasone (VRd) Followed By Ciltacabtagene Autoleucel Versus Vrd Followed By Lenalidomide and Dexamethasone (Rd) Maintenance in Patients with Newly Diagnosed Multiple Myeloma (NDMM) Not Intended for Transplant

Author

Agha, Mounzer, Dhakal, Binod, Dytfeld, Dominik, Manier, Salomon, Delforge, Michel, Kuppens, Steven, Afifi, Salma, Deraedt, William, Taraseviciute-Morris, Agne, Schecter, Jordan M, Gilbert, Jane, Yalniz, Fevzi, Florendo, Erika, Pacaud, Lida, Hungria, Vania, Usmani, Saad Z., and Mateos, Maria-Victoria

Published
2022
Full Text
View/download PDF

29. Bortezomib, Lenalidomide and Dexamethasone (VRd) Followed By Ciltacabtagene Autoleucel Versus Vrd Followed By Lenalidomide and Dexamethasone (Rd) Maintenance in Patients with Newly Diagnosed Multiple Myeloma Not Intended for Transplant: A Randomized, Phase 3 Study (CARTITUDE-5)

Author

Dytfeld, Dominik, Dhakal, Binod, Agha, Mounzer, Manier, Salomon, Delforge, Michel, Kuppens, Steven, Afifi, Salma, Deraedt, William, Taraseviciute-Morris, Agne, Schecter, Jordan M., Gilbert, Jane, Yalniz, Fevzi, Florendo, Erika, Pacaud, Lida, Hungria, Vania, Usmani, Saad Z., and Mateos, Maria-Victoria

Published
2021
Full Text
View/download PDF

31. Significance of minimal residual disease monitoring by real-time quantitative polymerase chain reaction in core binding factor acute myeloid leukemia for transplantation outcomes.

Author

Yalniz, Fevzi F., Patel, Keyur P., Bashir, Qaiser, Marin, David, Ahmed, Sairah, Alousi, Amin M., Chen, Julianne, Ciurea, Stefan O., Rezvani, Katy, Popat, Uday R., Shpall, Elizabeth J., Champlin, Richard E., and Oran, Betül

Subjects
*ACUTE myeloid leukemia, *POLYMERASE chain reaction, *HEMATOPOIETIC stem cell transplantation, *TRANSPLANTATION of organs, tissues, etc., *EXPERIMENTAL design
Abstract

Background: Despite the well-defined role of minimal residual disease (MRD) monitoring by real-time quantitative polymerase chain reaction (RT-PCR) for RUNX1/RUNX1T1 and CBFB-MYH11 transcripts in core binding factor (CBF) acute myeloid leukemia (AML) after intensive chemotherapy, there has been a paucity of data assessing the utility of MRD monitoring at and after allogeneic hematopoietic stem cell transplantation (HSCT).Methods: Patients with CBF AML who underwent HSCT in complete remission (first or second) from January 2007 through December 2018 were included in this analysis.Results: MRD by polymerase chain reaction at HSCT was assessed in 50 of 76 patients, and 44 (88%) had evidence of MRD (MRDpos). MRDpos patients had 3-year overall survival (OS) and leukemia-free survival (LFS) rates of 69.3% and 66.3%, respectively. Six MRD-negative patients had 3-year OS and LFS rates of 100% and 100%, respectively. Thirty-five of the 70 evaluable patients (50%) had a day +100 MRD assessment by RT-PCR, and 14 (40%) were MRDpos. The presence of MRD by RT-PCR on day +100 was not associated with lower estimates of LFS (75% vs 82.2%; P = .3) but was associated with a higher relapse incidence, although the difference did not reach statistical significance (27.6% vs 9.7%; P = .2).Conclusions: Durable complete remissions can be achieved in patients with CBF AML with HSCT even if they are MRDpos by RT-PCR at HSCT. The clinical impact of frequent MRD monitoring for identifying a group at high risk for early relapse and then for determining the best time point for therapeutic interventions to prevent impending relapse warrants investigation in prospectively designed clinical trials. [ABSTRACT FROM AUTHOR]

Published
2020
Full Text
View/download PDF

32. A phase II study of addition of pracinostat to a hypomethylating agent in patients with myelodysplastic syndromes who have not responded to previous hypomethylating agent therapy.

Author

Yalniz, Fevzi F., Berdeja, Jesus G., Maris, Michael B., Lyons, Roger M., Reeves, James A., Essell, James H., Patel, Prapti, Sekeres, Mikkael, Hughes, Amanda, Mappa, Silvia, and Garcia‐Manero, Guillermo

Subjects
*MYELODYSPLASTIC syndromes, *TERMINATION of treatment, *DISEASE progression, *BONE marrow, *ADVERSE health care events
Abstract

Summary: Hypomethylating agents (HMAs) are standard of care for higher‐risk myelodysplastic syndromes (MDS). However, less than half of patients achieve objective responses and most eventually lose their response. Pracinostat is a pan‐histone deacetylase inhibitor with demonstrated activity in advanced myeloid malignancies. This phase II study explored the benefit of adding pracinostat to HMAs in MDS patients who did not respond to single‐agent HMA treatment. The goal was to estimate the clinical improvement rate [complete remission (CR), marrow CR, partial response (PR) and haematological improvement]. Group 1 included patients with primary/secondary HMA failures; Group 2 included those who did not achieve response but had stable disease (SD) after single‐agent HMAs. Forty‐five patients (39 Group 1, 6 Group 2) received a median of 3 cycles. Among all patients, 1 (2%) had CR, 7 (16%) had marrow CR and 18 (40%) had SD; disease progression occurred in 3 (7%). Median overall survival was 5·7/5·6 months for Group 1/2. Grade ≥3 adverse events occurred in 38 patients (84%) leading to treatment discontinuation in 12 (33%). Adding pracinostat to HMAs did not improve outcomes in patients previously treated with HMAs. Frequent dose modifications/early discontinuation resulted in suboptimal drug exposure. A reduced pracinostat dose may improve tolerability and efficacy. [ABSTRACT FROM AUTHOR]

Published
2020
Full Text
View/download PDF

33. The Easix (Endothelial Activation and Stress Index) Score Predicts for CAR T Related Toxicity in Patients Receiving Axicabtagene Ciloleucel (axi-cel) for Non-Hodgkin Lymphoma (NHL)

Author

Greenbaum, Uri, Strati, Paolo, Saliba, Rima M., Torres, Janet, Rondon, Gabriela, Nieto, Yago, Hosing, Chitra, Srour, Samer A., Westin, Jason, Fayad, Luis, Lee, Hun Ju, Iyer, Swaminathan P, Nastoupil, Loretta J., Parmar, Simrit, Rodriguez, Maria Alma, Samaniego, Felipe, Steiner, Raphael Eric, Wang, Michael, Pinnix, Chelsea C., Flowers, Christopher, Tummala, Sudhakar, Ramdial, Jeremy, Yalniz, Fevzi F., Hawkins, Misha, Rezvani, Katayoun, Champlin, Richard E., Shpall, Elizabeth J., Neelapu, Sattva S., Kebriaei, Partow, and Ahmed, Sairah

Published
2020
Full Text
View/download PDF

36. Sorafenib plus intensive chemotherapy improves survival in patients with newly diagnosed, FLT3-internal tandem duplication mutation-positive acute myeloid leukemia.

Author

Sasaki, Koji, Kantarjian, Hagop M., Kadia, Tapan, Patel, Keyur, Loghavi, Sanam, Garcia‐Manero, Guillermo, Jabbour, Elias J., DiNardo, Courtney, Pemmaraju, Naveen, Daver, Naval, Dalle, Iman Abou, Short, Nicholas, Yilmaz, Musa, Bose, Prithviraj, Naqvi, Kiran, Pierce, Sherry, Yalniz, Fevzi, Cortes, Jorge E., Ravandi, Farhad, and Garcia-Manero, Guillermo

Subjects
ACUTE myeloid leukemia, SORAFENIB, STEM cell transplantation, PROPORTIONAL hazards models, PROPENSITY score matching, PRELEUKEMIA
Abstract

Background: The addition of midostaurin to induction chemotherapy improves survival in younger patients with newly diagnosed, FLT3-mutated acute myeloid leukemia (AML). Sorafenib is a potent multikinase inhibitor with efficacy when given as monotherapy. The authors investigated whether the addition of sorafenib to intensive induction chemotherapy improves outcomes in patients with FLT3-internal tandem duplication (ITD)-mutated AML.Methods: In total, 183 patients who were newly diagnosed with FLT3-ITD-mutated AML between February 2001 and December 2017 were identified. Of these, 79 patients (43%) underwent intensive chemotherapy with the addition of sorafenib, and 104 (57%) received intensive chemotherapy alone. Propensity score matching identified 42 patients in each cohort.Results: The overall response rate was 98% in the sorafenib cohort and 83% in the intensive chemotherapy cohort (P = .057). The median follow-up was 54 months. The median event-free survival was 35 months in the sorafenib cohort and 8 months in the intensive chemotherapy cohort (P = .019), and the median overall survival was 42 and 13 months, respectively (P = .026). With censoring at the time of allogeneic stem cell transplantation, the median event-free survival was 31 and 8 months in the sorafenib and intensive therapy cohorts, respectively (P = .031), and the median overall survival was not reached and 10 months, respectively (P = .001). Multivariate Cox proportional hazards models confirmed that treatment with sorafenib was a favorable prognostic factor (P = .009; hazard ratio, 0.558; 95% CI, 0.360-0.865).Conclusions: The addition of sorafenib improves survival in patients with FLT3-ITD-mutated AML regardless of whether they undergo allogeneic stem cell transplantation. [ABSTRACT FROM AUTHOR]

Published
2019
Full Text
View/download PDF

37. Prognostic significance of baseline FLT3-ITD mutant allele level in acute myeloid leukemia treated with intensive chemotherapy with/without sorafenib.

Author

Yalniz, Fevzi, Dalle, Iman Abou, Kantarjian, Hagop, Borthakur, Gautam, Kadia, Tapan, Patel, Keyur, Loghavi, Sanam, Garcia-Manero, Guillermo, Sasaki, Koji, Daver, Naval, DiNardo, Courtney, Pemmaraju, Naveen, Short, Nicholas J., Yilmaz, Musa, Bose, Prithviraj, Naqvi, Kiran, Pierce, Sherry, González, Graciela M. Nogueras, Konopleva, Marina, and Andreeff, Michael

Published
2019
Full Text
View/download PDF

38. Somatic Mutations Improve Risk Classification By Cytogenetic Abnormalities in Patients with Myelodysplastic Syndrome after Hematopoietic Stem Cell Transplantation

Author

Yalniz, Fevzi F., Saliba, Rima M., Yucel, Orhan K., Garcia-Manero, Guillermo, Ramdial, Jeremy, Popat, Uday, Ciurea, Stefan O., Kebriaei, Partow, Alousi, Amin M., Alatrash, Gheath, Bashir, Qaiser, Hosing, Chitra, Marin, David, Mehta, Rohtesh, Olson, Amanda L., Rezvani, Katayoun, Shpall, Elizabeth J., Rondon, Gabriela, Champlin, Richard E., and Oran, Betul

Published
2019
Full Text
View/download PDF

40. Prognostic Significance of Baseline FLT3-ITD Mutant Allele Burden in Acute Myeloid Leukemia Treated with Intensive Chemotherapy with/without Sorafenib

Author

Yalniz, Fevzi, Kantarjian, Hagop M., Kadia, Tapan M., Garcia-Manero, Guillermo, Patel, Keyur, Loghavi, Sanam, Sasaki, Koji, Daver, Naval G., DiNardo, Courtney D., Pemmaraju, Naveen, Short, Nicholas J, Yilmaz, Musa, Bose, Prithviraj, Naqvi, Kiran, Pierce, Sherry A., Cortes, Jorge E., and Ravandi, Farhad

Published
2018
Full Text
View/download PDF

41. Third-line treatment with second-generation tyrosine kinase inhibitors (dasatinib or nilotinib) in patients with chronic myeloid leukemia after two prior TKIs: real-life data on a single center experience along with the review of the literature.

Author

Ongoren, Seniz, Eskazan, Ahmet Emre, Suzan, Veysel, Savci, Sercan, Erdogan Ozunal, Isil, Berk, Selin, Yalniz, Fevzi Fırat, Elverdi, Tugrul, Salihoglu, Ayse, Erbilgin, Yucel, Iseri, Sibel Aylin, Ar, Muhlis Cem, Baslar, Zafer, Aydin, Yildiz, Tuzuner, Nukhet, Ozbek, Ugur, and Soysal, Teoman

Subjects
PROTEIN-tyrosine kinase inhibitors, MYELOID leukemia, HEMATOPOIETIC stem cell transplantation, DRUG administration, LITERATURE reviews, PATIENTS
Abstract

Objectives: Newer tyrosine kinase inhibitors (TKIs) (bosutinib, ponatinib) and allogeneic hematopoietic stem cell transplantation (allo-HSCT) can be utilized as a salvage therapy in patients with chronic myeloid leukemia (CML) who failed two lines (imatinib → nilotinib or imatinib → dasatinib) of TKI therapy. However, these TKIs are not available in many countries and not all patients can undergo allo-HSCT. Methods: In this study, CML patients who received dasatinib or nilotinib as a third-line treatment were retrospectively evaluated. Results: Out of 209 patients, third-line dasatinib/nilotinib was administered in 21. During the follow-up, 16 out of 21 patients gained and/or maintained an optimal response, and 4 patients died due to progression. Seventeen patients were alive at the time of the analysis, of which 13 were still on TKI, whereas 4 patients quit treatment. Discussion: In patients failing two lines of TKI, dasatinib or nilotinib can be beneficial and safely administered as a third-line treatment especially in nations with restricted resources. [ABSTRACT FROM AUTHOR]

Published
2018
Full Text
View/download PDF

42. Real-World Data in Relapsed Refractory Myeloma Patients Treated with Carfilzomib, a Multicenter Turkish Experience

Author

Sevindik, Omur Gokmen, Pehlivan, Mustafa, Tuglular, Tulin F, Solmaz, Serife M, Dogu, Mehmet Hilmi, Yalniz, Fevzi, Ural, Ali Ugur, Yeğen, Zafer Serenli, Arat, Mutlu, Ozkocaman, Vildan, Umit, Elif G, Şahin, Handan Haydaroğlu, Sönmez, Mehmet, Turgut, Mehmet, Ozcan, Muhit, Arslan, Onder, Aydin, Yildiz, Elibol, Tayfun, Harmandali Olgun, Aybuke, Bayar, Banu, Tombak, Anil, Aydogdu, Ismet, and Özsan, Güner Hayri

Published
2017
Full Text
View/download PDF

44. Prognostic Role of Gene Mutations in Chronic Myelomonocytic Leukemia (CMML) Patients Treated with Hypomethylating Agents. a Report on 183 Patients

Author

Duchmann, Matthieu, Yalniz, Fevzi, Sanna, Alessandro, Sallman, David A, Coombs, Catherine C., Renneville, Aline, Kosmider, Olivier, Braun, Thorsten, Platzbecker, Uwe, Willems, Lise, Ades, Lionel, Fontenay, Michaela, Rampal, Raajit K., Padron, Eric, Droin, Nathalie, Preudhomme, Claude, Santini, Valeria, Patnaik, Mrinal M., Fenaux, Pierre, Solary, Éric, and Itzykson, Raphael

Published
2017
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results